Ziritaxestat, also known as GLPG1690, is a selective autotaxin inhibitor discovered by Galapagos, with potential application in idiopathic pulmonary disease (IPF). In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement.
PDE Inhibitors Related Products:
Roflumilast; Sildenafil citrate; Cilomilast; Tadalafil; Pimobendan; GSK256066; Mardepodect; Rolipram; Apremilast; Milrinone; Avanafil; Ibudilast; Balipodect; PF8380; Deltarasin; Anagrelide hydrochloride; Enpp-1-IN-1; Crisaborole; CP671305